Published in Circulation on March 17, 2008
Monocyte recruitment during infection and inflammation. Nat Rev Immunol (2011) 7.55
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 4.95
ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science (2010) 4.67
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 3.85
Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol (2010) 3.53
Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation (2010) 3.37
Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science (2013) 3.22
Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol (2011) 2.44
Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest (2011) 2.37
TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest (2010) 2.32
Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med (2008) 2.22
Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation (2009) 2.19
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Monocyte trafficking in acute and chronic inflammation. Trends Immunol (2011) 2.05
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91
Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.79
Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.76
Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation (2013) 1.65
Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 1.61
Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers. PLoS One (2011) 1.60
Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J Neurosci (2011) 1.59
CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol (2009) 1.57
Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest (2012) 1.57
Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol (2009) 1.57
Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology (2011) 1.57
Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A (2009) 1.56
The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol (2009) 1.55
Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest: short communication. Circ Res (2014) 1.50
Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res (2013) 1.47
Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol (2016) 1.46
Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes (2011) 1.44
CCR2(+) monocytes infiltrate atrophic lesions in age-related macular disease and mediate photoreceptor degeneration in experimental subretinal inflammation in Cx3cr1 deficient mice. EMBO Mol Med (2013) 1.42
Regulation of inflammatory monocyte/macrophage recruitment from the bone marrow during murine cytomegalovirus infection: role for type I interferons in localized induction of CCR2 ligands. J Immunol (2009) 1.40
Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov (2010) 1.38
Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol (2011) 1.29
Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med (2012) 1.28
The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul Pharmacol (2009) 1.27
CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation (2010) 1.18
CX3CR1 deficiency does not influence trafficking of adipose tissue macrophages in mice with diet-induced obesity. Obesity (Silver Spring) (2012) 1.17
Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation. Arterioscler Thromb Vasc Biol (2011) 1.16
Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm (2012) 1.16
Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med (2013) 1.15
Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol (2009) 1.13
CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stresses. J Exp Med (2010) 1.10
The fate of monocytes in atherosclerosis. J Thromb Haemost (2009) 1.09
Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol (2015) 1.08
Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond) (2011) 1.07
Air pollution-mediated susceptibility to inflammation and insulin resistance: influence of CCR2 pathways in mice. Environ Health Perspect (2013) 1.05
Monocyte heterogeneity in cardiovascular disease. Semin Immunopathol (2013) 1.05
NADPH oxidase 4 mediates monocyte priming and accelerated chemotaxis induced by metabolic stress. Arterioscler Thromb Vasc Biol (2011) 1.05
Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. Protein Cell (2012) 1.03
Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Circ Res (2016) 1.03
Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol (2012) 1.02
Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation (2010) 1.02
Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin (2013) 1.02
Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol (2015) 1.02
Single nucleotide polymorphisms in MCP-1 and its receptor are associated with the risk of age related macular degeneration. PLoS One (2012) 1.01
Macrophage autophagy in atherosclerosis. Mediators Inflamm (2013) 1.00
Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis. Circ Res (2014) 1.00
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev (2015) 1.00
ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium. Arterioscler Thromb Vasc Biol (2011) 0.98
Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circ Res (2011) 0.96
Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency. Arterioscler Thromb Vasc Biol (2014) 0.96
How dendritic cells shape atherosclerosis. Trends Immunol (2011) 0.96
Chemokines and microRNAs in atherosclerosis. Cell Mol Life Sci (2015) 0.94
Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends Endocrinol Metab (2012) 0.94
From proliferation to proliferation: monocyte lineage comes full circle. Semin Immunopathol (2014) 0.93
Dynamic immune cell accumulation during flow-induced atherogenesis in mouse carotid artery: an expanded flow cytometry method. Arterioscler Thromb Vasc Biol (2012) 0.93
Making a difference: monocyte heterogeneity in cardiovascular disease. Curr Atheroscler Rep (2012) 0.93
Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med (2010) 0.93
Molecular control of monocyte development. Cell Immunol (2014) 0.92
RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality. Proc Natl Acad Sci U S A (2015) 0.91
Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol (2014) 0.91
Central IKKβ inhibition prevents air pollution mediated peripheral inflammation and exaggeration of type II diabetes. Part Fibre Toxicol (2014) 0.91
Functional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis. J Cell Mol Med (2009) 0.91
Macrophages in vascular inflammation--From atherosclerosis to vasculitis. Autoimmunity (2015) 0.91
Reactive oxygen species and thiol redox signaling in the macrophage biology of atherosclerosis. Antioxid Redox Signal (2012) 0.90
Macrophage differentiation and function in atherosclerosis: opportunities for therapeutic intervention? J Innate Immun (2012) 0.90
High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther (2010) 0.90
Monocytes link atherosclerosis and cancer. Eur J Immunol (2011) 0.90
Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol (2013) 0.90
Clinical significance of monocyte heterogeneity. Clin Transl Med (2015) 0.90
Ischemia/reperfusion injury: The role of immune cells. World J Cardiol (2010) 0.89
p53 is an important regulator of CCL2 gene expression. Curr Mol Med (2012) 0.89
Foamy monocytes form early and contribute to nascent atherosclerosis in mice with hypercholesterolemia. Arterioscler Thromb Vasc Biol (2015) 0.89
Exaggerated effects of particulate matter air pollution in genetic type II diabetes mellitus. Part Fibre Toxicol (2014) 0.89
Myeloid cells in atherosclerosis: a delicate balance of anti-inflammatory and proinflammatory mechanisms. Curr Opin Lipidol (2013) 0.88
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J (2013) 0.88
Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. Expert Opin Drug Discov (2012) 0.87
Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection. PLoS One (2010) 0.86
Fractalkine promotes human monocyte survival via a reduction in oxidative stress. Arterioscler Thromb Vasc Biol (2014) 0.85
Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease. J Immunol Res (2014) 0.85
Disordered haematopoiesis and athero-thrombosis. Eur Heart J (2016) 0.85
Stage-specific remodeling of atherosclerotic lesions upon cholesterol lowering in LDL receptor knockout mice. Am J Pathol (2011) 0.84
Effects of a novel pharmacologic inhibitor of myeloperoxidase in a mouse atherosclerosis model. PLoS One (2012) 0.84
Deciphering the stromal and hematopoietic cell network of the adventitia from non-aneurysmal and aneurysmal human aorta. PLoS One (2014) 0.84
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation (2004) 5.28
Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev (2006) 5.27
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med (2006) 4.28
Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55
Comparison of routine and on-demand prescription of chest radiographs in mechanically ventilated adults: a multicentre, cluster-randomised, two-period crossover study. Lancet (2009) 3.33
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 2.87
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 2.35
TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest (2010) 2.32
Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 2.21
Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol (2005) 2.20
Lactadherin promotes VEGF-dependent neovascularization. Nat Med (2005) 2.19
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med (2009) 2.17
Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res (2013) 2.05
Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation (2007) 2.00
Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension (2006) 1.99
Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.98
Endothelial microparticles in diseases. Cell Tissue Res (2008) 1.96
Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 1.94
Selection of intensive care unit admission criteria for patients aged 80 years and over and compliance of emergency and intensive care unit physicians with the selected criteria: An observational, multicenter, prospective study. Crit Care Med (2009) 1.88
BAFF receptor deficiency reduces the development of atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol (2012) 1.87
CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol (2008) 1.82
p47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling. Circ Res (2005) 1.81
Microparticles, vascular function, and atherothrombosis. Circ Res (2011) 1.78
Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol (2007) 1.72
Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology (2012) 1.69
Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab (2010) 1.68
Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res (2003) 1.68
Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res (2014) 1.68
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 1.68
Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J (2012) 1.66
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol (2011) 1.65
A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. Cardiovasc Res (2012) 1.63
Cellular mechanics and gene expression in blood vessels. J Biomech (2003) 1.63
Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation (2003) 1.59
Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries. Circ Res (2006) 1.58
Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol (2011) 1.57
Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol (2008) 1.56
Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition. Cardiovasc Res (2007) 1.54
Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme. J Hypertens (2002) 1.54
Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation (2004) 1.48
Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA (2012) 1.48
Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv (2012) 1.47
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
Circulating microparticles may influence early carotid artery remodeling. J Hypertens (2010) 1.45
Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers. Circulation (2010) 1.44
Smooth muscle dysfunction in resistance arteries of the staggerer mouse, a mutant of the nuclear receptor RORalpha. Circ Res (2002) 1.44
The role of adaptive T cell immunity in atherosclerosis. J Lipid Res (2008) 1.43
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43